Hemoglobinopathies 

1. Faller DV: Vascular Perturbations in Sickle Cell Disease. In: The Sickle Hemoglobinopathies: Science and Medicine. Embury SH, Hebbel RP, Narla M and Steinberg MH, eds. Raven Press, New York, 1994, pp. 235-247.
2. Perrine SP, Cohen, RA, Greene MF, and Faller DV: In vitro studies on infants with inhibition of the fetal globin switch. Thalassemia Today: The Mediterranean Experience. Eds. G. Sirchia and A. Zanella (Milano Editore, Milano, 1987), p. 439-441.
3. Perrine SP, Greene MF and Faller DV: Inhibition of the fetal globin switch in infants of diabetic mothers. New Engl J Med., 1985, 312:334-338.
4. Perrine SP, Kan YW, Rubin, EM, Cooper, SL. Cohen RA, Romano, C, Rudolph A and Faller DV: Inhibition of developmental globin gene switching in vivo in human and ovine fetuses. In: Developmental Control of Globin Gene Expression. (G. Stamatoyannopoulos and A. Nienhuis, eds.) Alan R. Liss, New York, 1986, p. 545-556.
5. Perrine SP, Cohen RA, Mille, BA, Greene MF and Faller DV: Developmental studies on the human fetal globin switch. In: Molecular Approaches to Developmental Biology Firtel, R.A. and Davidson, E.H., eds. U.C.L.A. Symposium on Molecular and Cellular Biology, Vol. 51, (Alan R. Liss, New York, 1987), p. 501-508.
6. Perrine SP, Greene MF, Cohen RA and Faller DV: Delayed fetal globin switching in infants of diabetic mothers is associated with specific DNA hypomethylation. 1988, FEBS Letters, 228:139-143.
7. Perrine SP, Faller DV, Swerdlow P, Miller BA, Sytkowski AJ, Reczek J, Rudolph AM, and Kan YW: Stopping the biologic clock for globin gene switching. 1990, Ann. New York Acad. Sci., 612:134 40.
8. Perrine SP, Faller, DV, Swerdlow P., Miller BA., Rudolph, AM, and Kan YW: Pharmacologic inhibition or reversal of developmental globin gene switching. In: Hemoglobin Switching, Part B: Cellular and Molecular Mechanisms. (G. Stamatoyannopoulos and A. Nienhuis, eds.) 1991. Alan R. Liss, New York.
9. Perrine SP: Fetal globin induction - Can it cure beta thalassemia? 2005. American Society of Hematology Educational Program, pp. 38-44.

Short Chain Fatty Acids and SCFADs 

1. Atweh G, Ikuta T White G, Boosalis V, Da Fonseca S, Boosalis M, Dover G, Faller DV and Perrine SP: Cellular and molecular effects of butyrate and carboxylic acid derivatives on globin gene expression and hematopoiesis. 1988, Ann New York Acad. Sci., p. 87-99.
2. Atweh GF, Sutton M, Nassif I, Boosalis V., Dover GJ, Wright E, McMahon L, Stamatoyannopoulos G, Faller, DV, and Perrine SP: Sustained induction of fetal hemoglobin by pulsing butyrate therapy in sickle cell disease. 1999, Blood, 93:1790-1797.
3. Bohacek R, Boosalis MS, McMartin C., Faller DV and Perrine SP.: Identification of novel small molecule inducers of fetal hemoglobin using pharmacophore and "pseudo" receptor models. 2006, Chem Biol Drug Des., 67:318-28.
4. Boosalis M, Ikuta T, Pace BS, Da Fonseca White GL, Faller DV and Perrine SP: Abrogation of IL-3 requirements and stimulation of hematopoietic proliferation in vitro and in vivo by carboxylic acids. 1997, Blood Cells Mol Dis., 23:434-42
5. Boosalis M, Bandyopadhyay R, Faller, DV and Perrine SP: Short-chain fatty acid derivatives stimulate cell proliferation and induce Stat5 activation. 2001, Blood, 97:3259-3267.
6. Brauer M, Almomen AK and Faller DV: Butyrate treatment in beta-hemoglobinopathies. 1995, N. Engl. J. Med., 333, 1287.
7. Cao H, Stamatoyannopoulos G and Jung M: Induction of human gamma globin gene expression by histone deacetylase inhibitors. 2004, Blood, 103:701-709.
8. Casteneda S, Boosalis MS, Emery D, Thies A, Faller DV and Perrine SP: Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. 2005, Blood Mol Cell and Dis., 35:217-26.
9. Chen JS, Faller DV and Spanjaard RA: Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? 2003, Current Cancer Drug Targets, 3:219-236.
10. Costin D, Atweh GF, Mazza P,Sutton M, Brauer M, Ikuta T, Rizzo C, Dover G, Faller DV and Perrine SP: Pilot trials of two butyrate-based therapeutic agents in the beta-globin disorders. In: Molecular Biology of Hemoglobin Switching, Vol 1. (G. Stamatoyannopoulos, ed.) 1995. Intercept (Andover, United Kingdom), Chapter 28, pp. 353-364.
11. Faller DV and Perrine SP: Butyrate in the treatment of sickle cell disease and beta thalassemia. Curr Opin Hematol 1995, 2:109-117.
12. Fibach E, Prosmanne J, Rodgers GP and Samid D: Enhanced fetal hemoglobin production by phenylacetate and phenylbutyrate in erythroid precursor derived from normal donors and patients with sickle cell anemia and beta-thalassemia. 1993, Blood, 82:2203.
13. Ikuta T, Atweh G, Boosalis V, White GL, DA Fonseca S, Boosali M, Faller DV and Perrine SP: Cellular and molecular effects pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis. 1998, Ann N Y Acad Sci., 850:87-99.
14. Ikuta T, Swerdlow PS, Berg, P Kan, YW, Faller DV and Perrine SP: Alterations in protein-DNA interactions in the -globin locus in humans in response to butyrate therapy. 1998, Blood, 92:2924-2933.
15. Liakopoulou E, Blau CA, Li Q, Josephson B, Wolf J, Fournarakis B, Raisys V, Dover G, Papayannoulou and Stamatoyannopoulos G: Stimulation of fetal hemoglobin production by short chain fatty acids. 1995, 86:3227-3235.
16. Liakopoulou E, Li Q and Stamatoyannoulos G: Induction of fetal hemoglobin by propionic acid and butyric acid derivatives: correlations between chemical structure and potency of Hb F induction. 2002, 29:48-56.
17. Mankidy R, Faller, DV, Bohacek R and Perrine SP: Short-chain fatty acids induce? -globin gene expression by displacement of a HDAC3-NCOR repressor complex. 2006, Blood 108:3179-186.
18. Nishino T, Cao H, Stammatoyannopoulos G and Emery DS: Effects of human gamma-globin in murine beta-thalassemia. 2006, Br J Haematol., 134:100-108.
19. Oliveri NF and Weatherall DJ: The therapeutic reactivation of fetal hemoglobin. 1998, Hum Molec Genet., 7:1655-1658.
20. Pace BS, White, GL, and Dover GJ, Boosalis MS, Faller, DV and Perrine SP: Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. 2002, Blood, 100:4640-4648.
21. Perrine SP, Miller BA, Greene, MF, Cohen, RA, Cook N, Hazleton C and Faller DV: Butyric acid analogues augment analogues augment beta-globin gene expression in neonatal erythroid progenitors. 1987, Biochem and Biophys Res Comm., 148:694-700.
22. Perrine, SP, Rudolph a, Faller DV, Roman C, Cohen, RA, Chen, SJ, and Kan YW: Butyrate infusions in the ovine fetal delay the biologic clock for globin gene switching. 1988, Proc. Natl Acad Sci., USA, 85:8540-8542.
23. Perrine SP, Miller BA, Faller DV, Cohen, RA, Vichinsky EP, Hurst D, Lubin BH and Papayannapoulou Th: Sodium butyrate stimulates fetal globin gene expression in erythroid progenitors of beta-thalassemia children with HbSS and 1989, Blood, 74:454-460.
24. Perrine S, Miller B, Papayannopoulou Th, Faller DV, Rudolph A, Vichinsky E, Hurst D, and Kan YW: Butyrate analogues modulate globin gene expression in human and ovine erythroid cells. 1989, Prog Clin Biol Res., 16:341-350.
25. Perrine SP, Swerdlow P, Faller DV, Qin G, Rudolph AM, Reczek J. and Kan YW: Butyric acid modulates developmental globin gene switching in man and sheep. 1989, Adv Exp Med Biol., 271:177 83.
26. Perrine SP and Faller DV: Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the hemoglobinopathies. 1993, Experientia, 49:133-137.
27. Perrine SP, Ginder G., Faller DV, Kan YW, Jin XX and Olivieri NF: A short-term trial of butyrate to stimulate fetal globin gene expression in the beta globin gene disorders. 1993, New Engl J Med., 328:81-86.
28. Perrine SP, Walsh CT, Jin YX, Dover G, Mays A, and Faller DV: Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo. 1994, Br J Haem., 88:555-561.
29. Perrine SP, Olivieri NF, Faller DV, Vichinsky EP, Dover GJ and Ginder GD: Butyrate derivatives: New agents for stimulating fetal globin in the beta globin disorders. 1994, Am J Ped Hem Onc., 16:67-71.
30. Perrine SP, Castenada SA, Boosalis MS, White GL, Jones MB and Bohacek R: Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress. 2005, Ann N Y Acad Sci., 1054:257-65.
31. Stamatoyannopoulos G, Blau CA, Nakamoto B, Josephson B, Li Q, Liakopoulou E, Pace B, Papayannopoulou T, Brusilow SW and Dover G: Fetal hemoglobin induction by acetate, a product of butyrate catabolism. 1994, Blood, 84:3198.
32. Vaziri C, Stice LL, and Faller DV: Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma-mediated signals. 1999, Cell Growth Differ 9:465.
33. Weinberg RS, Ji X, Sutton M, Perrine S, Galperin Y, Li Q, Liebhaber SA, Stammatoyannopoulos G and Atweh GF: Butyrate increases the efficiency of translation of gamma-globin mRNA. 2005, Blood 105:1807-1809.
34. White GL, Daftari P, Dover GJ, White B, Torkelson S, Fournarakis B, Faller DV and Perrine SP: Stimulation of erythropoiesis and Hb F in vivo with oral hemokines. 1996, Blood, 88:495a

Virus-Associated Cancer 

1. Faller, DV Mentzer SJ., and Perrine SP: Induction of the Epstein-Barr Virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for EBV-associated malignancies. 2001, Curr Opin Oncol., 13:360-367.
2. Ghosh SK, Forman LW, Akinsheye I, Perrine SP and Faller DV: Short discontinuous sodium butyrate exposure efficiently sensitizes latently EBV infected cells towards nucleoside analogue-mediated growth inhibition. 2007, Blood Cell Mol Diseases, in press.
3. Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein- Barr virus (EBV)-associated lymphoma. 1998, Blood Cells Molecules.Dis., 24:114-23.
4. Mentzer SJ, Perrine, SP and Faller DV: Epstein-Barr Virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with Arginine Butyrate. 2001, Transplant Infect Dis., 3:177-185.
5. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Mentzer SJ, Levy A, DiNicola M, Klein C, Horwitz S and Faller DV: A Phase I/II study of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. 2007, Blood, in press.

About Us  Our Technology  Clinical  Partnerships  Newsroom  Careers  Contact Us  Terms of Use  Privacy Policy

Copyright © 2008 HemaQuest Pharmaceuticals, Inc. All rights reserved.